Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

doi:10.1200/JCO.2008.20.1061

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 May 2009

Lara Primo N, Natale Ronald, Crowley John, Lenz Heinz Josef, Redman Mary W, Carleton Jane E, Jett James, Langer Corey J, Kuebler J Philip, Dakhil Shaker R, Chansky Kari, Gandara David R

Abstract excerpt

PURPOSE: Irinotecan plus cisplatin (IP) improved survival over etoposide plus cisplatin (EP) in Japanese patients with extensive-stage small-cell lung cancer (E-SCLC). To confirm those results and discern the potential role of population-related pharmacogenomics (PG) in outcomes, we conducted a large randomized trial of identical design to the Japanese trial in North American patients with E-SCLC. PATIENTS AND...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Camptothecin

Share to Cisplatin

Share to Etoposide

Share to Glucuronosyltransferase

Share to Irinotecan

Share to Neutropenia

Share to Small Cell Lung Carcinoma

Source

Open in PubMed Open full text

Identifiers

PMID: 19349543
DOI: 10.1200/JCO.2008.20.1061
PMCID: PMC2684855

Genes

ABCB1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.PMID 19349543Read ↗

Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Model for Assessing Population-Related PharmacogenomicsSemantic proximity Read ↗

A genome-wide association study of survival in small-cell lung cancer patients treated with irinotecan plus cisplatin chemotherapy.Semantic proximity Read ↗

The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncology.Semantic proximity Read ↗

Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small-cell lung cancer: protocol of IRICO studySemantic proximity Read ↗

Highlights from the latest articles in pharmacogenomics of irinotecan/cisplatin toxicity.Semantic proximity Read ↗

A genome-wide association study for irinotecan-related severe toxicities in patients with advanced non-small-cell lung cancer.Semantic proximity Read ↗

Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Phase II study of S-1 and irinotecan combination therapy in EGFR-mutated non-small cell lung cancer resistant to epidermal growth factor receptor tyrosine kinase inhibitor: North Japan Lung Cancer Study Group Trial 0804 (NJLCG0804).Semantic proximity Read ↗

Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Pemetrexed and cisplatin for advanced non-squamous non-small cell lung cancer in Japanese patients: phase II study.Semantic proximity Read ↗

Population-based differences in treatment outcome following anticancer drug therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.